A COVID-19 Risk Reduction Strategy for the Treatment of Acute Vogt-Koyanagi-Harada Disease Utilizing the Antiviral Potential of Cyclosporine

References

• Sonoda KH, Hasegawa E, and Namba K, et al. Epidemiology of uveitis in Japan: a 2016 retrospective nationwide survey. Jpn J Ophthalmol. 2021;65:184–190. doi:10.1007/s10384-020-00809-1.
   PubMed Web of Science ®Google Scholar
• Chee SP, Jap A, Bacsal K. Prognostic factors of Vogt-Koyanagi-Harada disease in Singapore. Am J Ophthalmol. 2009;147(1):154–161.e1. doi:10.1016/j.ajo.2008.07.044.
   PubMed Web of Science ®Google Scholar
• Ohno S; Japanese Ocular Inflammation Society Uveitis Clinical Guidelines Committee. Committee chair). guidelines for uveitis (in Japanese). Nippon Ganka Gakkai Zasshi. 2019;123:635–696.
   Google Scholar
• Nakayama M, Keino H, Watanabe T, et al. Clinical features and visual outcomes of 111 patients with new-onset acute Vogt-Koyanagi-Harada disease treated with pulse intravenous corticosteroids. Br J Ophthalmol. 2019;103(2):274–278. doi:10.1136/bjophthalmol-2017-311691.
   PubMed Web of Science ®Google Scholar
• Zierhut M, De Smet MD, Gupta V, et al. Evolving consensus experience of the IUSG-IOIS-FOIS with uveitis in the time of COVID-19 infection. Ocul Immunol Inflamm. 2020;28(5):709–713. doi:10.1080/09273948.2020.1780273.
   PubMed Web of Science ®Google Scholar
• Agrawal R, Testi I, Lee SC, COVID-19 IMT Study Group. Evolving consensus for immunomodulatory therapy in non-infectious uveitis during the COVID-19 pandemic. Br J Ophthalmol. 2021;105(5):639–647. doi:10.1136/bjophthalmol-2020-316776.
   PubMed Web of Science ®Google Scholar
• Marques CDL, Kakehasi AM, Pinheiro MM, et al. High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of reumaCoV Brasil registry. RMD Open. 2021;7(1):e001461.doi:10.1136/rmdopen-2020-001461.
   PubMed Web of Science ®Google Scholar
• de Wilde Ah, Zevenhoven-Dobbe JC, van der Meer Y, et al. Cyclosporin A inhibits the replication of diverse coronaviruses. J Gen Virol. 2011;92:2542–2548. doi:10.1099/vir.0.034983-0.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Sato Y, Sasaki T. Suppression of coronavirus replication to cyclophilin inhibitors. Viruses. 2013;5(5):1250–1260. doi:10.3390/v5051250.
   PubMed Web of Science ®Google Scholar
• Rudnicka L, Glowacka P, Goldust M, et al. Cyclosporine therapy during the COVID-19 pandemic. J Am Acad Dermatol. 2020;83:e151–e152. doi:10.1016/j.jaad.2020.04.153.
   PubMed Web of Science ®Google Scholar
• Poulsen NN, Von Brunn A, Hornum M, Jensen MB. Cyclosporine and COVID-19: risk or favorable? Am J Transplant. 2020;20(11):2975–2982. doi:10.1111/ajt.16250.
   PubMed Web of Science ®Google Scholar
• Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110–118. doi:10.1016/j.jaci.2020.04.006.
   PubMed Web of Science ®Google Scholar
• Neurath MF. COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology. Nat Rev Gastroenterol Hepatol. 2021;18(10):705–715. doi:10.1038/s41575-021-00480-y.
   PubMed Web of Science ®Google Scholar
• Burke KE, Kochar B, Allegretti JR, et al. Immunosuppressive therapy and risk of COVID-19 infection in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2021;27:155–161. doi:10.1093/ibd/izaa278.
   PubMed Web of Science ®Google Scholar
• Tassone D, Thompson A, Connell W, et al. Immunosuppression as a risk factor for COVID −19: a meta-analysis. Int Med J. 2021;51(2):199–205. doi:10.1111/imj.15142.
   Google Scholar
• Fung M, Babik JM. COVID-19 in immunocompromised hosts: what we know so far. Clin Infect Dis. 2021;71(2):340–350. doi:10.1093/cid/ciaa863.
   Google Scholar
• Zhang M, Bai X, and Cao W, et al. The influence of corticosteroids, immunosuppressants and biologics on patients with inflammatory bowel diseases, psoriasis and rheumatic diseases in the era of COVID-19: a review of current evidence. Front Immunol. 2021. doi:10.3389/fimmu.2021.677957.
   Web of Science ®Google Scholar
• Zuniga MAL, Moreno-Moral A, and Ocana-Granados A , et al. High-dose corticosteroid pulse therapy increases the survival rate in COVID-19 patients at risk of hyper-inflammatory response. PlosOne. 2021. doi:10.1371/journal.pone.0243964.
   Google Scholar
• COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed Sept 22 2021.
   Google Scholar
• Mikuls TR, Johnson SR, Fraenkel L, et al. American College of Rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 3. Arthritis Rheum. 2021;73:e1–e12.
   Web of Science ®Google Scholar
• Wahezi DM, Lo MS, Rubinstein TB, et al. American college of rheumatology guidance for the management of pediatric rheumatic disease suring th eCOVID-19 pandemic: version 2. Arthritis Rheum. 2021;73:e46–e59.
   Web of Science ®Google Scholar
• Devaux CA, Melenotte C, Piercecchi-Marti M-D, et al. Cyclosporin A: a repuposable drug in the treatment of COVID-19? Front Med. 2021;8:663708. doi:10.3389/fmed.2021.663708.
   Web of Science ®Google Scholar
• Hosoda Y, Hayashi H, and Kuriyama S. Posterior subtenon triamcinolone acetonide injection as a primary treatment in eyes with acute Vogt-Koyanagi-Harada disease. Br J Ophthalmol 2015;99:1211–1214.
   Google Scholar
• Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature11The authors constitute the International Committee on Vogt-Koyanagi-Harada Disease Nomenclature, representing the participants of the First International Workshop on Vogt-Koyanagi-Harada Disease. A full list of participants appears at the end of the article. Am J Ophthalmol. 2001;131(5):647–652. doi:10.1016/S0002-9394(01)00925-4.
   PubMed Web of Science ®Google Scholar
• Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859–866. doi:10.1136/annrheumdis-2020-217871.
   PubMed Web of Science ®Google Scholar